NxStage Medical, Inc. (NASDAQ:NXTM) – Research analysts at Jefferies Group cut their FY2017 earnings per share (EPS) estimates for shares of NxStage Medical in a research note issued on Tuesday. Jefferies Group analyst R. Denhoy now forecasts that the medical device company will earn ($0.06) per share for the year, down from their prior forecast of ($0.05). Jefferies Group currently has a “Hold” rating and a $30.00 target price on the stock.

NxStage Medical (NASDAQ:NXTM) last released its quarterly earnings results on Monday, August 7th. The medical device company reported ($0.03) earnings per share (EPS) for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.03). NxStage Medical had a negative return on equity of 2.46% and a negative net margin of 1.33%. The business had revenue of $92.20 million during the quarter, compared to analyst estimates of $96.47 million. During the same quarter in the previous year, the company posted ($0.03) earnings per share. NxStage Medical’s revenue for the quarter was up .0% on a year-over-year basis.

TRADEMARK VIOLATION NOTICE: “Research Analysts Set Expectations for NxStage Medical, Inc.’s FY2017 Earnings (NXTM)” was originally reported by Watch List News and is the property of of Watch List News. If you are accessing this news story on another domain, it was copied illegally and republished in violation of United States & international copyright legislation. The original version of this news story can be viewed at https://www.watchlistnews.com/research-analysts-set-expectations-for-nxstage-medical-inc-s-fy2017-earnings-nxtm/1467423.html.

Several other brokerages also recently weighed in on NXTM. Northland Securities downgraded NxStage Medical from an “outperform” rating to a “market perform” rating in a research report on Thursday, May 4th. BidaskClub raised NxStage Medical from a “hold” rating to a “buy” rating in a research report on Friday, June 30th. William Blair downgraded NxStage Medical from an “outperform” rating to a “market perform” rating in a research report on Monday. BTIG Research reaffirmed a “buy” rating and set a $27.00 price target on shares of NxStage Medical in a research report on Wednesday, May 10th. Finally, Canaccord Genuity downgraded NxStage Medical from a “buy” rating to a “hold” rating and set a $30.00 price target on the stock. in a research report on Monday. One investment analyst has rated the stock with a sell rating, six have given a hold rating and two have assigned a buy rating to the stock. The stock presently has a consensus rating of “Hold” and an average target price of $30.29.

Shares of NxStage Medical (NASDAQ NXTM) opened at 29.29 on Thursday. The firm’s 50-day moving average price is $24.57 and its 200 day moving average price is $25.80. NxStage Medical has a 12-month low of $20.45 and a 12-month high of $30.80. The company’s market cap is $1.93 billion.

In other news, President Joseph E. Turk, Jr. sold 7,000 shares of the firm’s stock in a transaction dated Thursday, August 3rd. The stock was sold at an average price of $22.98, for a total transaction of $160,860.00. Following the sale, the president now directly owns 82,903 shares in the company, valued at approximately $1,905,110.94. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, President Joseph E. Turk, Jr. sold 1,000 shares of the firm’s stock in a transaction dated Wednesday, July 5th. The shares were sold at an average price of $25.19, for a total value of $25,190.00. Following the sale, the president now owns 75,903 shares in the company, valued at $1,911,996.57. The disclosure for this sale can be found here. Insiders have sold a total of 52,900 shares of company stock worth $1,374,813 over the last ninety days. 4.70% of the stock is owned by insiders.

Large investors have recently bought and sold shares of the stock. SG Americas Securities LLC acquired a new stake in NxStage Medical during the first quarter worth approximately $140,000. Ameritas Investment Partners Inc. acquired a new stake in NxStage Medical during the first quarter worth approximately $148,000. Quantitative Systematic Strategies LLC acquired a new stake in NxStage Medical during the second quarter worth approximately $203,000. Menta Capital LLC acquired a new stake in NxStage Medical during the first quarter worth approximately $212,000. Finally, Jane Street Group LLC acquired a new stake in NxStage Medical during the first quarter worth approximately $213,000. Hedge funds and other institutional investors own 91.11% of the company’s stock.

NxStage Medical Company Profile

NxStage Medical, Inc is a medical technology company. The Company develops, manufactures and markets products and services for patients suffering from chronic or acute kidney failure. It operates through three segments. The System One segment includes revenues from the sale and rental of the System One and PureFlow SL dialysate preparation equipment and the sale of disposable products in the home and critical care markets.

Earnings History and Estimates for NxStage Medical (NASDAQ:NXTM)

Receive News & Ratings for NxStage Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NxStage Medical Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.